Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.
Also called NCT01376557
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 299 participants
- Sponsor
- Registry
-
NCT01376557
-
- Other papers using this trial's data
- Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01376557. Randomized; quadruple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2014-10-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- 75 mg LX4211
- Intervention (Drug)
- 200 mg LX4211
- Intervention (Drug)
- 400 mg LX4211
- Intervention (Drug)
- 200 mg LX4211
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lexicon Pharmaceuticals
Record details
- Record id
cardio:ct-nct01376557- Content hash
4bbd1acc10d8b284ea3945d98f2981b2dbdbf5f8a2d41add27ed8abf784be8d7